Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NUVL Nuvalent, Inc.

盘后交易 06-30 18:48:39 EDT

123.50

-0.01

-0.01%

盘后123.50

+0.000.00%

16:11 EDT

最高123.56	最低123.43	成交量165.40万
今开123.52	昨收123.51	日振幅0.11%
总市值97.54亿	流通市值71.56亿	总股本7,898万
成交额2.04亿	换手率2.85%	流通股本5,794万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NUVL","market":"US","secType":"STK","nameCN":"Nuvalent, Inc.","latestPrice":123.5,"timestamp":1782849600000,"preClose":123.51,"halted":0,"volume":1653970,"hourTrading":{"tag":"盘后","latestPrice":123.5,"preClose":123.5,"latestTime":"16:11 EDT","volume":13622,"amount":1682317,"timestamp":1782850286244,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00008096510404020012,"floatShares":57942920,"shares":78978000,"eps":-6.06,"marketStatus":"盘后交易","change":-0.01,"latestTime":"06-30 18:48:39 EDT","open":123.52,"high":123.56,"low":123.43,"amount":204252005,"amplitude":0.001053,"askPrice":124.52,"askSize":1,"bidPrice":123.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.06,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782864000000},"marketStatusCode":4,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":123.51,"preHourTrading":{"tag":"盘前","latestPrice":123.52,"preClose":123.51,"latestTime":"09:29 EDT","volume":7290,"amount":900627.3765,"timestamp":1782826199999,"change":0.01,"changeRate":0.000081,"amplitude":0.004592},"postHourTrading":{"tag":"盘后","latestPrice":123.5,"preClose":123.5,"latestTime":"16:11 EDT","volume":13622,"amount":1682317,"timestamp":1782850286244,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.896072,"impliedVol":0.0416,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NUVL","defaultTab":"news","newsList":[{"id":"2645281618","title":"葛兰素史克宣布要约收购Nuvalent。","url":"https://stock-news.laohu8.com/highlight/detail?id=2645281618","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645281618?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:54","pubTimestamp":1782309271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","NUVL","GSK","BK4585","GSKH","BK4588","LU1829250122.USD","BK4539","BK4532","GSK.UK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135318827","title":"伯恩斯坦下调Nuvalent评级至“与大盘持平”，目标价大幅削减至124美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135318827","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135318827?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:30","pubTimestamp":1782307813,"startTime":"0","endTime":"0","summary":"伯恩斯坦分析师对Nuvalent, Inc.的评级进行了显著调整，将其从“跑赢大盘”下调至“与大盘持平”。与此同时，该机构将Nuvalent的目标股价从172美元大幅削减至124美元，显示出对公司前景看法的重大转变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642189402","title":"重返肿瘤核心战场 葛兰素史克(GSK.US)能否借Nuvalent缩小与阿斯利康差距？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642189402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642189402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:56","pubTimestamp":1781164594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克以创纪录的106亿美元收购美国生物技术公司Nuvalent，此举将加快这家英国制药巨头旗下抗癌药物业务的重建步伐，以应对来自更大竞争对手阿斯利康和罗氏的竞争压力。米尔斯在周二宣布收购Nuvalent后对记者表示。葛兰素史克并不打算在全部肿瘤领域与默沙东、阿斯利康或罗氏正面竞争，但将其视为潜在的增长领域。收购Nuvalent将为葛兰素史克产品组合增添两款晚期药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4568","LU0889565916.HKD","BK4585","IE00B3T34201.USD","LU2237443895.HKD","GSK.UK","LU0320765992.SGD","AZNH","LU2237443622.USD","BK4539","AZN","LU2462157665.USD","LU2456880835.USD","BK4139","LU1829250122.USD","LU2237443382.USD","LU2237443549.SGD","LU0058720904.USD","NUVL","LU0289739699.SGD","LU2236285917.USD","GSKH","LU2417539215.USD","LU2237443465.HKD","GSK","BK4007","LU2237443978.SGD","BK4532","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156980149","title":"医疗健康板块热点速递：市场动态一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1156980149","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156980149?lang=zh_cn&edition=full","pubTime":"2026-06-10 04:53","pubTimestamp":1781038402,"startTime":"0","endTime":"0","summary":"最新一期医疗健康板块市场动态速递。此次上调规模表明，市场对Apotex及其股东出售股票的需求强劲，足以支持其超越最初的计划。葛兰素史克股价下跌1.3%。瑞银分析师维持对该股的买入评级，但在给客户的报告中警告称，市场普遍预测CSL血浆制品业务利润率将扩大90个基点，这一预期过高。他们预计，每位捐赠者采集量增长10%将带来改善，并称这将有助于抵消价格和竞争压力。股价上涨0.6%至98.49澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4588","XBI","NUVL","BK4581","XLV","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642671094","title":"Nuvalent股价飙升 此前GSK宣布收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2642671094","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642671094?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:10","pubTimestamp":1781007000,"startTime":"0","endTime":"0","summary":"英国生物制药公司葛兰素史克宣布以106亿美元收购美国药企Nuvalent，后者股价随即飙升近39%。\n　　这项全现金交易对Nuvalent的估值约为每股124美元。Nuvalent目前有两款治疗某种肺癌的药物正在接受美国食品药品监督管理局的审评。\n　　葛兰素史克首席执行官卢克·米尔斯在新闻稿中表示，此次收购将为公司带来即时的新的销售增长机遇。这家药企在美国上市的股票周二盘前交易中下跌1%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniavmyr1715814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK.UK","BK4139","BK4588","BK4532","BK4585","GSK","LU1829250122.USD","NUVL","BK4539","BK4007","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193786930","title":"若协议在特定条件下终止，Nuvalent需向葛兰素史克支付3.5048亿美元终止费 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1193786930","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193786930?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:07","pubTimestamp":1781003237,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件披露，生物制药公司Nuvalent, Inc.已与葛兰素史克达成协议，规定若双方协议在特定条件下被终止，Nuvalent将需向GSK支付一笔高达3.5048亿美元的终止费用。支付如此高额的终止费，凸显了该合作协议对Nuvalent的战略重要性，同时也反映了GSK为保障其潜在权益而设置的关键财务保障措施。市场将密切关注双方合作的后续进展，以及任何可能触发该条款的事态发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642668054","title":"英国葛兰素史克斥资106亿美元收购美国药企Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2642668054","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642668054?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:28","pubTimestamp":1780997280,"startTime":"0","endTime":"0","summary":"英国制药集团葛兰素史克达成协议，以 106 亿美元收购美国药企 Nuvalent。本次收购正值全球生物医药并购热潮期。　　英国制药巨头葛兰素史克敲定收购美国药企 Nuvalent 的交易，交易总价 106 亿美元，核心目的是补强自身肺癌药物管线。　　葛兰素史克周二披露公告显示，本次交易为全现金收购，对 Nuvalent 的估值折合每股 124 美元，较该股前一交易日收盘价溢价 40%。　　英国《金融时报》周二早间率先曝出该并购消息，Nuvalent 方面暂未回应媒体置评请求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniauzkq6465243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","BK4007","GSK.UK","NUVL","GSKH","BK4532","BK4139","GSK","LU1829250122.USD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642468769","title":"Nuvalent盘前上涨38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642468769","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642468769?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:09","pubTimestamp":1780992569,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvalent盘前上涨38%至每股122.5美元，葛兰素史克提出以每股124美元的价格收购该公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606093765128193.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765128193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100807568","title":"盘前异动 | 芯片股延续涨势，迈威尔科技、美光科技涨超3%；Nuvalent涨超38%，获葛兰素史克溢价收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1100807568","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100807568?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:03","pubTimestamp":1780992196,"startTime":"0","endTime":"0","summary":"6月9日，美股三大股指期货齐涨，截止发稿，道指期货涨0.6%，纳指期货涨0.27%，标普500指数期货涨0.39%。芯片股延续涨势，$迈威尔科技$、$美光科技$、$高通$涨超3%，$ARM$、$闪迪$、$西部数据$、$希捷$数据、$Cerebras Systems$、$安森美半导体$涨超2%，$英特尔$、$AMD$涨超1%；$Applied Digital$涨超10%，与美国超大规模用户签署52亿美元AI数据中心租约；$Nuvalent$涨超38%，$葛兰素史克$拟以106亿美元收购该公司，加码癌症药物领域。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRVU","MU","NUVL","MRVL","MULL","MVLL","MUU","MUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642450645","title":"溢价40%！葛兰素史克拟以106亿美元收购Nuvalent，加码癌症药物领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2642450645","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642450645?lang=zh_cn&edition=full","pubTime":"2026-06-09 15:37","pubTimestamp":1780990654,"startTime":"0","endTime":"0","summary":"6月9日，$葛兰素史克$同意以106亿美元的价格收购肿瘤治疗药企Nuvalent。$葛兰素史克$周二发布声明称，将以每股124美元现金收购Nuvalent，较这家总部位于马萨诸塞州$剑桥$的公司周一收盘价溢价40%。此次收购标志着葛兰素史克癌症业务的重大扩张。Nuvalent的两款主要药物用于治疗携带特定基因突变的非小细胞肺癌患者。葛兰素史克表示，在获得监管部门批准后，对Nuvalent的收购预计将于第三季度完成。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451912.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"溢价40%！葛兰素史克拟以106亿美元收购Nuvalent，加码癌症药物领域","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK4539","BK4532","GSKH","BK4139","LU1829250122.USD","BK4007","GSK","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182801706","title":"葛兰素史克CEO解释Nuvalent交易规模超常规：单笔交易获多款产品“不寻常”","url":"https://stock-news.laohu8.com/highlight/detail?id=1182801706","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182801706?lang=zh_cn&edition=full","pubTime":"2026-06-09 15:13","pubTimestamp":1780989220,"startTime":"0","endTime":"0","summary":"葛兰素史克首席执行官卢克·米尔斯表示，公司与Nuvalent, Inc.达成的交易规模之所以超出常规范围，原因在于单笔交易即能获得多款产品的情况实属“不寻常”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1645745479.HKD","BK4539","LU2089984988.USD","LU0225283273.USD","LU0161305163.EUR","LU1046248800.SGD","LU1487256676.USD","LU2646069778.SGD","LU0203347892.USD","LU0321505868.SGD","LU0289739699.SGD","SGXZ57979304.SGD","NUVL","LU0109981661.USD","LU1015430645.USD","LU0306806265.USD","LU0971552673.USD","LU0987226296.USD","LU0306807586.USD","IE00B3T34201.USD","LU1202635105.USD","LU1228905037.USD","LU1481600234.SGD","IE00BWDBJ516.SGD","LU0058720904.USD","LU1302929846.USD","LU1400636574.HKD","LU1400636657.SGD","LU2468319806.SGD","LU0575583348.USD","LU1481599808.USD","LU1670756490.USD","SG9999001176.SGD","LU0225771236.USD","BK4139","LU1064927863.SGD","BK5011","LU0971552830.HKD","LU1035777561.USD","LU1983299246.USD","LU0225284248.USD","IE00BQJZX424.USD","LU0557290698.USD","LU1309081286.SGD","GSK.UK","LU0985481810.HKD","LU1228905540.USD","LU0321505439.SGD","LU0203345920.USD","LU0545562505.USD","LU1098665638.USD","SG9999013999.USD","LU0211331839.USD","IE0034235071.USD","SG9999001176.USD","LU1400636491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131432437","title":"葛兰素史克将接手Nuvalent与Royalty Pharma及Deerfield的低个位数特许权使用费收入分成协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1131432437","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131432437?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:02","pubTimestamp":1780984941,"startTime":"0","endTime":"0","summary":"葛兰素史克宣布，将承接Nuvalent公司现有的收入分成安排，即向Royalty Pharma及Deerfield支付低个位数百分比的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU1645745479.HKD","LU1228905540.USD","LU0211331839.USD","LU1202635105.USD","LU0225284248.USD","LU1228905037.USD","SG9999013999.USD","LU1670756490.USD","LU1481599808.USD","LU1400636657.SGD","LU0545562505.USD","LU0225771236.USD","LU1046248800.SGD","LU1302929846.USD","LU2646069778.SGD","NUVL","IE0034235071.USD","LU0306806265.USD","SGXZ57979304.SGD","LU0306807586.USD","BK4139","GSK.UK","LU0058720904.USD","LU1035777561.USD","LU0321505868.SGD","LU0203345920.USD","LU0971552830.HKD","LU0225283273.USD","LU0971552673.USD","IE00BQJZX424.USD","BK5011","LU2089984988.USD","SG9999001176.USD","LU1098665638.USD","LU0987226296.USD","LU0321505439.SGD","LU1309081286.SGD","LU0161305163.EUR","SG9999001176.SGD","LU2468319806.SGD","LU0575583348.USD","BK4539","LU1015430645.USD","LU0985481810.HKD","LU1064927863.SGD","LU0203347892.USD","LU0289739699.SGD","LU0109981661.USD","LU1400636491.USD","LU1400636574.HKD","LU1481600234.SGD","LU1487256676.USD","LU0557290698.USD","LU1983299246.USD","IE00BWDBJ516.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642567024","title":"最高溢价近43%!葛兰素史克(GSK.US)拟斥资90-100亿美元收购肿瘤药企Nuvalent(NUVL.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642567024","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642567024?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:18","pubTimestamp":1780975127,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克正就收购肿瘤治疗药企Nuvalent Inc.进行磋商，交易对价在90亿至100亿美元之间。本次交易将对总部位于马萨诸塞州剑桥市的Nuvalent给出高额溢价，这也将成为葛兰素史克史上规模最大的收购案之一。在退出肿瘤领域多年后，葛兰素史克近期才重新回归这一赛道。今年1月，葛兰素史克曾同意以22亿美元收购一家专注于炎症与免疫疾病治疗药物研发的美国生物科技公司Rapt Therapeutics，并在另一笔交易中获得了一款肺动脉高压药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","BK4139","BK4532","GSK.UK","LU1829250122.USD","NUVL","GSKH","GSK","BK4585","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195440784","title":"最高溢价近43%！葛兰素史克拟斥资90-100亿美元收购肿瘤药企Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=1195440784","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195440784?lang=zh_cn&edition=full","pubTime":"2026-06-09 09:14","pubTimestamp":1780967654,"startTime":"0","endTime":"0","summary":"6月9日，癌症生物技术公司Nuvalent夜盘涨超16%。据市场消息，葛兰素史克正就收购Nuvalent进行谈判，交易作价可能超过90亿美元，双方目标在本周内达成协议。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1451825.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["GSKH","GSK","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172180016","title":"Nuvalent公布关键项目与业务进展，巩固其在ROS1与ALK阳性非小细胞肺癌领域的全球领导地位基础","url":"https://stock-news.laohu8.com/highlight/detail?id=1172180016","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172180016?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:30","pubTimestamp":1779877820,"startTime":"0","endTime":"0","summary":"Nuvalent公司宣布了其关键研发项目与业务运营的重要更新，此举进一步夯实了该公司在针对ROS1与ALK阳性非小细胞肺癌治疗领域，实现全球领导地位的战略根基。这些进展涵盖了从管线推进到企业运营的多个层面，彰显了公司致力于为患者带来变革性疗法的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138597174","title":"Nuvalent公司：现有资金、现金等价物及有价证券足以支撑其运营至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1138597174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138597174?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:40","pubTimestamp":1778150425,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvalent, Inc.宣布，其现有的现金储备、现金等价物以及可流通有价证券，预计将能够为公司的持续运营和研发活动提供充足的资金支持，直至2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164810657","title":"Nuvalent公布近期管线进展，重申关键预期里程碑及2026年第一季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1164810657","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164810657?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:34","pubTimestamp":1778150073,"startTime":"0","endTime":"0","summary":"Nuvalent公司近日重点介绍了其研发管线的最新进展，再次明确了未来关键的预期里程碑节点，并同步发布了2026年第一季度的财务报告。\n公司管理层在更新中强调了其在研项目取得的实质性推进，同时重申了对即将到来的重要发展时间点的预期。此外，2026年首季的财务业绩数据也一并公布，为投资者提供了全面的运营和财务视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144205337","title":"Nuvalent向FDA提交新药申请，寻求批准Neladalkib用于TKI经治的ALK阳性晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1144205337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144205337?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:33","pubTimestamp":1775557994,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvalent, Inc.宣布，已正式向美国食品药品监督管理局（FDA）提交了其研究性药物Neladalkib的新药申请（NDA）。该申请旨在寻求批准Neladalkib用于治疗既往接受过酪氨酸激酶抑制剂（TKI）治疗的间变性淋巴瘤激酶（ALK）阳性晚期非小细胞肺癌（NSCLC）患者。\n这一重要监管里程碑标志着该药物在开发进程中迈出了关键一步，若获批准，将为这类患者群体提供一个新的潜在治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160862794","title":"Nuvalent公布近期研发管线进展，重申关键预期里程碑，并报告2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1160862794","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160862794?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:32","pubTimestamp":1772105558,"startTime":"0","endTime":"0","summary":"Nuvalent, Inc. (纳斯达克代码: NUVL) 近日披露了其研发管线的最新动态，再次强调了未来重要的预期里程碑节点，同时公布了公司2025财年第四季度及全年的财务业绩报告。\n公司管理层详细介绍了其在研项目取得的实质性进展，特别是在靶向疗法领域。这些进展进一步巩固了其在精准肿瘤学药物开发方面的领先地位。与此同时，财务数据显示了公司在战略投资研发与维持财务健康之间取得的平衡。\n此次信息更新为投资者和行业观察人士提供了评估公司未来发展轨迹和潜在价值的关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NUVL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600308304","title":"Nuvalent, Inc.跌0.40% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2600308304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600308304?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:31","pubTimestamp":1767191464,"startTime":"0","endTime":"0","summary":"北京时间2025年12月31日22时31分，Nuvalent, Inc.股票出现波动，股价快速跳水0.40%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Vanda Pharmaceuticals Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Fibrobiologics, Inc.、Gri Bio, Inc.、Pmgc Holdings Inc.较为活跃，换手率分别为22.66%、14.08%、14.01%，振幅较大的相关个股有Gri Bio, Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Outlook Therapeutics, Inc.，振幅分别为7.66%、7.41%、5.90%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231223105a6e5f6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231223105a6e5f6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","NUVL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvalent.com","stockEarnings":[{"period":"1week","weight":0.0007},{"period":"1month","weight":0.1189},{"period":"3month","weight":0.2056},{"period":"6month","weight":0.2279},{"period":"1year","weight":0.5501},{"period":"ytd","weight":0.2279}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.1394},{"period":"6month","weight":0.0866},{"period":"1year","weight":0.2051},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nuvalent, Inc.于2017年1月25日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。该公司利用团队在化学和基于结构的药物设计方面的深厚专业知识，开发创新的小分子，其设计旨在克服现有疗法对临床证明的激酶靶点的限制。目前可用的激酶抑制剂面临的限制可能包括（i）激酶耐药性，或激酶靶点出现新的突变，从而能够对现有疗法产生耐药性，（ii）激酶选择性，或现有疗法可能抑制结构相似的激酶靶点并导致脱靶不良事件，以及（iii）有限的脑外显率，或该疗法治疗已经扩散或转移到大脑的疾病的能力。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":-0.027036},{"month":2,"riseRate":0.6,"avgChangeRate":0.018654},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073231},{"month":4,"riseRate":0.4,"avgChangeRate":0.01512},{"month":5,"riseRate":0.4,"avgChangeRate":0.015248},{"month":6,"riseRate":1,"avgChangeRate":0.165938},{"month":7,"riseRate":1,"avgChangeRate":0.08966},{"month":8,"riseRate":0.6,"avgChangeRate":0.217715},{"month":9,"riseRate":0.8,"avgChangeRate":0.02208},{"month":10,"riseRate":0.8,"avgChangeRate":0.213383},{"month":11,"riseRate":0.6,"avgChangeRate":0.048468},{"month":12,"riseRate":0.2,"avgChangeRate":-0.069265}],"exchange":"NASDAQ","name":"Nuvalent, Inc.","nameEN":"Nuvalent, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nuvalent, Inc.(NUVL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nuvalent, Inc.,NUVL,Nuvalent, Inc.股票,Nuvalent, Inc.股票老虎,Nuvalent, Inc.股票老虎国际,Nuvalent, Inc.行情,Nuvalent, Inc.股票行情,Nuvalent, Inc.股价,Nuvalent, Inc.股市,Nuvalent, Inc.股票价格,Nuvalent, Inc.股票交易,Nuvalent, Inc.股票购买,Nuvalent, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nuvalent, Inc.(NUVL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}